New treatment options for immune-mediated hematological disorders.

Abstract

In recent years, there has been a tremendous increase in the number of clinical studies with monoclonal antibodies and small molecules in the treatment of hematological malignancies. Clinical observations have shown that some of these molecules may also aid in the treatment of immune-mediated hematological disorders. Moreover, immunotherapy has become an important treatment cornerstone in other, non-hematological, auto-immune diseases. This paper reviews the current state of the use of these new molecules in the treatment of the most frequently encountered immune-mediated hematological disorders: auto-immune hemolytic anemia (AIHA), idiopathic thrombocytopenic purpura (ITP), and thrombotic thrombocytopenic purpura (TTP).

• Authors: Daan Dierickx, Anja De Rycke, Steven Vanderschueren, André Delannoy
• Journal: European journal of internal medicine (Eur J Intern Med) Vol. 19 Issue 8 Pg. 579-86 (Dec 2008) ISSN: 1879-0828 [Electronic] Netherlands
• PMID: 19046722 (Publication Type: Journal Article, Review)

Chemical References

• Adrenal Cortex Hormones
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Immunologic Factors
• Immunosuppressive Agents
• Rituximab

Topics

• Adrenal Cortex Hormones (therapeutic use)
• Anemia, Hemolytic, Autoimmune (drug therapy, immunology)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Clinical Trials as Topic
• Drug Therapy, Combination
• Evidence-Based Medicine
• Hematologic Diseases (drug therapy, immunology)
• Humans
• Immunologic Factors (therapeutic use)
• Immunosuppressive Agents (therapeutic use)
• Purpura, Thrombocytopenic, Idiopathic (drug therapy, immunology)
• Purpura, Thrombotic Thrombocytopenic (drug therapy, immunology)
• Rituximab
• Splenectomy
• Treatment Outcome